Phase 1 Randomised, Single-centre, Observer-blind, Placebo-controlled Trial of Safety and Immunogenicity of EN41-UGR7C HIV Vaccine Candidate Administered Intramuscularly in Healthy Female Volunteers
Latest Information Update: 04 Jul 2014
Price :
$35 *
At a glance
- Drugs HIV vaccine-PX-Therapeutics (Primary) ; Aluminium
- Indications HIV infections
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Sponsors PX Therapeutics
- 20 May 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2013 New trial record